Arcturus Therapeutics

Arcturus Therapeutics is a preclinical drug delivery and RNA medicines company. We are focused on developing novel technologies to build the next generation of safe, effective RNA and DNA medicines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics.

Placeholder

Arcturus Therapeutics

  • Arcturus Therapeutics Expands Platform with STARR Technology™READ MORE
  • Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis FoundationREAD MORE
  • Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License AgreementREAD MORE
  • Synthetic GenomicsArcturus Therapeutics Announces Strategic Alliance with Synthetic Genomics, Inc. to develop self-amplifying RNA-based vaccines and therapeuticsREAD MORE
  • Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA MedicinesREAD MORE

LUNAR®-mediated delivery of RNA into cells

LUNAR particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.

News & Events

  • November 7, 2019

    Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

    • November 7 2019
    • 0
    read more
  • November 7, 2019

    Arcturus Therapeutics Expands Platform with STARR Technology™

    • November 7 2019
    • 0
    read more
  • November 4, 2019

    Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th

    • November 4 2019
    • 0
    read more
  • October 2, 2019

    Arcturus Therapeutics to Present at Three Upcoming Investor Conferences

    • October 2 2019
    • 0
    read more
  • September 26, 2019

    Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock

    • September 26 2019
    • 0
    read more
  • September 23, 2019

    Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors

    • September 23 2019
    • 0
    read more
  • August 26, 2019

    Arcturus Therapeutics To Present at Two Investor Conferences in September

    • August 26 2019
    • 0
    read more
  • August 15, 2019

    Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update

    • August 15 2019
    • 0
    read more
  • August 7, 2019

    Arcturus to Report Corporate Overview and Financial Results on August 15

    • August 7 2019
    • 0
    read more